ISTODAX- romidepsin
Celgene Corporation
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ISTODAX safely and effectively. See full prescribing information for ISTODAX.
ISTODAX® (romidepsin) for injection For intravenous infusion only Initial U.S. Approval: 2009 RECENT MAJOR CHANGESIndications and Usage, peripheral T-cell lymphoma (1) 06/2011 Warnings and Precautions, Infection (5.2) 06/2011 Warnings and Precautions, Tumor Lysis Syndrome (5.4) 06/2011 Warnings and Precautions, Use in Pregnancy (5.5) 9/2011 Warnings and Precautions, Use in Women of Childbearing Potential (deleted) 9/2011 Update Manufacturing Information 3/2012 INDICATIONS AND USAGEISTODAX is a histone deacetylase (HDAC) inhibitor indicated for:
These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated (1). DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSISTODAX for injection, 10 mg, supplied with one Diluent vial containing 2 mL (deliverable volume) of solution (3). CONTRAINDICATIONSNone. (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions were neutropenia, lymphopenia, thrombocytopenia, infections, nausea, fatigue, vomiting, anorexia, anemia, and ECG T-wave changes (6). To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 03/2012 |
ISTODAX is indicated for:
These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
The recommended dose of romidepsin is 14 mg/m2 administered intravenously over a 4-hour period on days 1, 8, and 15 of a 28-day cycle. Cycles should be repeated every 28 days provided that the patient continues to benefit from and tolerates the drug.
Nonhematologic toxicities except alopecia
Hematologic toxicities
ISTODAX should be handled in a manner consistent with recommended safe procedures for handling cytotoxic drugs.
ISTODAX must be reconstituted with the supplied diluent and further diluted with 0.9% Sodium Chloride Injection, USP before intravenous infusion.
The diluted solution is compatible with polyvinyl chloride (PVC), ethylene vinyl acetate (EVA), polyethylene (PE) infusion bags as well as glass bottles, and is chemically stable for at least 24 hours when stored at room temperature. However, it should be administered as soon after dilution as possible.
Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit.
ISTODAX is supplied as a kit which includes a sterile, lyophilized powder in a single-use vial containing 10 mg of romidepsin and 20 mg of the bulking agent, povidone, USP. In addition, each kit includes 1 sterile vial containing 2 mL (deliverable volume) of the Diluent composed of 80% propylene glycol, USP, and 20% dehydrated alcohol, USP.
Treatment with ISTODAX can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia; therefore, these hematological parameters should be monitored during treatment with ISTODAX, and the dose should be modified, as necessary [See Dosage and Administration (2.2) and Adverse Reactions (6)].
Serious and sometimes fatal infections, including pneumonia and sepsis, have been reported in clinical trials with ISTODAX. These can occur during treatment and within 30 days after treatment, and the risk of life threatening infections may be higher in patients with a history of extensive or intensive chemotherapy [See Adverse Reactions (6)].
Several treatment-emergent morphological changes in ECGs (including T-wave and ST-segment changes) have been reported in clinical studies. The clinical significance of these changes is unknown [See Adverse Reactions (6)].
In patients with congenital long QT syndrome, patients with a history of significant cardiovascular disease, and patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation, appropriate cardiovascular monitoring precautions should be considered, such as the monitoring of electrolytes and ECGs at baseline and periodically during treatment.
Potassium and magnesium should be within the normal range before administration of ISTODAX [See Adverse Reactions (6)].
Tumor lysis syndrome (TLS) has been reported to occur in 1% of patients with tumor stage CTCL and 2% of patients with Stage III/IV PTCL. Patients with advanced stage disease and/or high tumor burden should be closely monitored, appropriate precautions should be taken, and treatment should be instituted as appropriate.
There are no adequate and well-controlled studies of ISTODAX in pregnant women. However, based on its mechanism of action and findings in animals, ISTODAX may cause fetal harm when administered to a pregnant woman. In an animal reproductive study, romidepsin was embryocidal and resulted in adverse effects on the developing fetus at exposures below those in patients at the recommended dose of 14 mg/m2/week. If this drug is used during pregnancy, or if the patient becomes pregnant while taking ISTODAX, the patient should be apprised of the potential hazard to the fetus [See Use in Specific Populations (8.1)].
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ISTODAX was evaluated in 185 patients with CTCL in 2 single arm clinical studies in which patients received a starting dose of 14 mg/m2. The mean duration of treatment in these studies was 5.6 months (range: <1 to 83.4 months).
Common Adverse Reactions
Table 1 summarizes the most frequent adverse reactions (> 20%) regardless of causality using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0). Due to methodological differences between the studies, the AE data are presented separately for Study 1 and Study 2. Adverse reactions are ranked by their incidence in Study 1. Laboratory abnormalities commonly reported (>20%) as adverse reactions are included in Table 1.
Adverse Reactions n (%) | Study 1 (n=102) | Study 2 (n=83) |
||
---|---|---|---|---|
All | Grade 3 or 4 | All | Grade 3 or 4 | |
Any adverse reaction | 99 (97) | 36 (35) | 83 (100) | 68 (82) |
Nausea | 57 (56) | 3 (3) | 71 (86) | 5 (6) |
Asthenia/Fatigue | 54 (53) | 8 (8) | 64 (77) | 12 (14) |
Infections | 47 (46) | 11 (11) | 45 (54) | 27 (33) |
Vomiting | 35 (34) | 1 (<1) | 43 (52) | 8 (10) |
Anorexia | 23 (23) | 1 (<1) | 45 (54) | 3 (4) |
Hypomagnesemia | 22 (22) | 1 (<1) | 23 (28) | 0 |
Diarrhea | 20 (20) | 1 (<1) | 22 (27) | 1 (1) |
Pyrexia | 20 (20) | 4 (4) | 19 (23) | 1 (1) |
Anemia | 19 (19) | 3 (3) | 60 (72) | 13 (16) |
Thrombocytopenia | 17 (17) | 0 | 54 (65) | 12 (14) |
Dysgeusia | 15 (15) | 0 | 33 (40) | 0 |
Constipation | 12 (12) | 2 (2) | 32 (39) | 1 (1) |
Neutropenia | 11 (11) | 4 (4) | 47 (57) | 22 (27) |
Hypotension | 7 (7) | 3 (3) | 19 (23) | 3 (4) |
Pruritus | 7 (7) | 0 | 26 (31) | 5 (6) |
Hypokalemia | 6 (6) | 0 | 17 (20) | 2 (2) |
Dermatitis/Exfoliative dermatitis | 4 (4) | 1 (<1) | 22 (27) | 7 (8) |
Hypocalcemia | 4 (4) | 0 | 43 (52) | 5 (6) |
Leukopenia | 4 (4) | 0 | 38 (46) | 18 (22) |
Lymphopenia | 4 (4) | 0 | 47 (57) | 31 (37) |
Alanine aminotransferase increased | 3 (3) | 0 | 18 (22) | 2 (2) |
Aspartate aminotransferase increased | 3 (3) | 0 | 23 (28) | 3 (4) |
Hypoalbuminemia | 3 (3) | 1 (<1) | 40 (48) | 3 (4) |
Electrocardiogram ST-T wave changes | 2 (2) | 0 | 52 (63) | 0 |
Hyperglycemia | 2 (2) | 2 (2) | 42 (51) | 1 (1) |
Hyponatremia | 1 (<1) | 1 (<1) | 17 (20) | 2 (2) |
Hypermagnesemia | 0 | 0 | 22 (27) | 7 (8) |
Hypophosphatemia | 0 | 0 | 22 (27) | 8 (10) |
Hyperuricemia | 0 | 0 | 27 (33) | 7 (8) |
Serious Adverse Reactions
Infections were the most common type of SAE reported in both studies with 8 patients (8%) in Study 1 and 26 patients (31%) in Study 2 experiencing a serious infection. Serious adverse reactions reported in > 2% of patients in Study 1 were sepsis and pyrexia (3%). In Study 2, serious adverse reactions in > 2% of patients were fatigue (7%), supraventricular arrhythmia, central line infection, neutropenia (6%), hypotension, hyperuricemia, edema (5%), ventricular arrhythmia, thrombocytopenia, nausea, leukopenia, dehydration, pyrexia, aspartate aminotransferase increased, sepsis, catheter related infection, hypophosphatemia and dyspnea (4%).
Most deaths were due to disease progression. In Study 1, there were two deaths due to cardiopulmonary failure and acute renal failure. In Study 2, there were six deaths due to infection (4), myocardial ischemia, and acute respiratory distress syndrome.
Discontinuations
Discontinuation due to an adverse event occurred in 21% of patients in Study 1 and 11% in Study 2. Discontinuations occurring in at least 2% of patients in either study included infection, fatigue, dyspnea, QT prolongation, and hypomagnesemia.
Peripheral T-Cell Lymphoma
The safety of ISTODAX was evaluated in 178 patients with PTCL in a sponsor-conducted pivotal study (Study 3) and a secondary NCI-sponsored study (Study 4) in which patients received a starting dose of 14 mg/m2. The mean duration of treatment and number of cycles in these studies were 5.6 months and 6 cycles.
Common Adverse Reactions
Table 2 summarizes the most frequent adverse reactions (≥ 10%) regardless of causality, using the NCI-CTCAE, Version 3.0. The AE data are presented separately for Study 3 and Study 4. Laboratory abnormalities commonly reported (≥ 10%) as adverse reactions are included in Table 2.
Adverse Reactions n (%) | Study 3 (N=131) | Study 4 (N=47) |
||
---|---|---|---|---|
All | Grade 3 or 4 | All | Grade 3 or 4 | |
Any adverse reactions | 127 (97) | 86 (66) | 47 (100) | 40 (85) |
Gastrointestinal disorders | ||||
Nausea | 77 (59) | 3 (2) | 35 (75) | 3 (6) |
Vomiting | 51 (39) | 6 (5) | 19 (40) | 4 (9) |
Diarrhea | 47 (36) | 3 (2) | 17 (36) | 1 (2) |
Constipation | 39 (30) | 1 (<1) | 19 (40) | 1 (2) |
Abdominal pain | 18 (14) | 3 (2) | 6 (13) | 1 (2) |
Stomatitis | 13 (10) | 0 | 3 (6) | 0 |
General disorders and administration site conditions | ||||
Asthenia/Fatigue | 72 (55) | 11 (8) | 36 (77) | 9 (19) |
Pyrexia | 46 (35) | 7 (5) | 22 (47) | 8 (17) |
Chills | 14 (11) | 1 (<1) | 8 (17) | 0 |
Edema peripheral | 13 (10) | 1 (<1) | 3 (6) | 0 |
Blood and lymphatic system disorders | ||||
Thrombocytopenia | 53 (41) | 32 (24) | 34 (72) | 17 (36) |
Neutropenia | 39 (30) | 26 (20) | 31 (66) | 22 (47) |
Anemia | 32 (24) | 14 (11) | 29 (62) | 13 (28) |
Leukopenia | 16 (12) | 8 (6) | 26 (55) | 21 (45) |
Metabolism and nutrition disorders | ||||
Anorexia | 37 (28) | 2 (2) | 21 (45) | 1 (2) |
Hypokalemia | 14 (11) | 3 (2) | 8 (17) | 1 (2) |
Nervous system disorders | ||||
Dysgeusia | 27 (21) | 0 | 13 (28) | 0 |
Headache | 19 (15) | 0 | 16 (34) | 1 (2) |
Respiratory, thoracic and mediastinal disorders | ||||
Cough | 23 (18) | 0 | 10 (21) | 0 |
Dyspnea | 17 (13) | 3 (2) | 10 (21) | 2 (4) |
Investigations | ||||
Weight decreased | 13 (10) | 0 | 7 (15) | 0 |
Cardiac disorders | ||||
Tachycardia | 13 (10) | 0 | 0 | 0 |
Serious Adverse Reactions
Infections were the most common type of SAE reported. In Study 3, 25 patients (19%) experienced a serious infection, including 6 patients (5%) with serious treatment-related infections. In Study 4, 11 patients (23%) experienced a serious infection, including 8 patients (17%) with serious treatment-related infections. Serious adverse reactions reported in ≥ 2% of patients in Study 3 were pyrexia (7%), pneumonia, sepsis, vomiting (5%), cellulitis, deep vein thrombosis, (4%), febrile neutropenia, abdominal pain (3%), chest pain, neutropenia, pulmonary embolism, dyspnea, and dehydration (2%). In Study 4, serious adverse reactions in ≥ 2 patients were pyrexia (17%), aspartate aminotransferase increased, hypotension (13%), anemia, thrombocytopenia, alanine aminotransferase increased (11%), infection, dehydration, dyspnea (9%), lymphopenia, neutropenia, hyperbilirubinemia, hypocalcemia, hypoxia (6%), febrile neutropenia, leukopenia, ventricular arrhythmia, vomiting, hypersensitivity, catheter related infection, hyperuricemia, hypoalbuminemia, syncope, pneumonitis, packed red blood cell transfusion, and platelet transfusion (4%).
Deaths due to all causes within 30 days of the last dose of ISTODAX occurred in 7% of patients in Study 3 and 17% of patients in Study 4. In Study 3, there were 5 deaths unrelated to disease progression that were due to infections, including multi-organ failure/sepsis, pneumonia, septic shock, candida sepsis, and sepsis/cardiogenic shock. In Study 4, there were 3 deaths unrelated to disease progression that were due to sepsis, aspartate aminotransferase elevation in the setting of Epstein Barr virus reactivation, and death of unknown cause.
Discontinuations
Discontinuation due to an adverse event occurred in 19% of patients in Study 3 and in 28% of patients in Study 4. In Study 3, thrombocytopenia and pneumonia were the only events leading to treatment discontinuation in at least 2% of patients. In Study 4, events leading to treatment discontinuation in ≥ 2 patients were thrombocytopenia (11%), anemia, infection, and alanine aminotransferase increased (4%).
Prolongation of PT and elevation of INR were observed in a patient receiving ISTODAX concomitantly with warfarin. Although the interaction potential between ISTODAX and Coumadin or Coumadin derivatives has not been formally studied, physicians should carefully monitor PT and INR in patients concurrently administered ISTODAX and Coumadin or Coumadin derivatives [See Clinical Pharmacology (12.3)].
Romidepsin is metabolized by CYP3A4. Although there are no formal drug interaction studies for ISTODAX, strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase concentrations of romidepsin. Therefore, co-administration with strong CYP3A4 inhibitors should be avoided if possible. Caution should be exercised with concomitant use of moderate CYP3A4 inhibitors.
Co-administration of potent CYP3A4 inducers (e.g., dexamethasone, carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital) may decrease concentrations of romidepsin and should be avoided if possible. Patients should also refrain from taking St. John's Wort.
Pregnancy Category D [See Warnings and Precautions (5.5)].
There are no adequate and well-controlled studies of ISTODAX in pregnant women. However, based on its mechanism of action and findings in animals, ISTODAX may cause fetal harm when administered to a pregnant woman. In an animal reproductive study, romidepsin was embryocidal and resulted in adverse effects on the developing fetus at exposures below those in patients at the recommended dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking ISTODAX, the patient should be apprised of the potential hazard to the fetus.
Romidepsin was administered intravenously to rats during the period of organogenesis at doses of 0.1, 0.2, or 0.5 mg/kg/day. Substantial resorption or post-implantation loss was observed at the high-dose of 0.5 mg/kg/day, a maternally toxic dose. Adverse embryo-fetal effects were noted at romidepsin doses of ≥0.1 mg/kg/day, with systemic exposures (AUC) ≥0.2% of the human exposure at the recommended dose of 14 mg/m2/week. Drug-related fetal effects consisted of folded retina, rotated limbs, and incomplete sternal ossification.
It is not known whether romidepsin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ISTODAX, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of ISTODAX in pediatric patients has not been established.
Of the approximately 300 patients with CTCL or PTCL in trials, about 25% were >65 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects; however, greater sensitivity of some older individuals cannot be ruled out.
No dedicated hepatic impairment study for ISTODAX has been conducted. Mild hepatic impairment does not alter pharmacokinetics of romidepsin based on a population pharmacokinetic analysis. Patients with moderate and severe hepatic impairment should be treated with caution [See Clinical Pharmacology (12.3)].
No dedicated renal impairment study for ISTODAX has been conducted. Based upon the population pharmacokinetic analysis, renal impairment is not expected to significantly influence drug exposure. The effect of end-stage renal disease on romidepsin pharmacokinetics has not been studied. Thus, patients with end-stage renal disease should be treated with caution [See Clinical Pharmacology (12.3)].
No specific information is available on the treatment of overdosage of ISTODAX.
Toxicities in a single-dose study in rats or dogs, at intravenous romidepsin doses up to 2.2 fold the recommended human dose based on the body surface area, included irregular respiration, irregular heart beat, staggering gait, tremor, and tonic convulsions.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., clinical monitoring and supportive therapy, if required. There is no known antidote for ISTODAX and it is not known if ISTODAX is dialyzable.
Romidepsin, a histone deacetylase (HDAC) inhibitor, is a bicyclic depsipeptide. At room temperature, romidepsin is a white powder and is described chemically as (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone. The empirical formula is C24H36N4O6S2.
The molecular weight is 540.71 and the structural formula is:
ISTODAX (romidepsin) for injection is intended for intravenous infusion only after reconstitution with the supplied Diluent and after further dilution with 0.9% Sodium Chloride, USP.
ISTODAX is supplied as a kit containing two vials.
ISTODAX (romidepsin) for injection is a sterile lyophilized white powder and is supplied in a single-use vial containing 10 mg romidepsin and 20 mg povidone, USP.
Diluent for ISTODAX is a sterile clear solution and is supplied in a single-use vial containing a 2-mL deliverable volume. Diluent for ISTODAX contains 80% (v/v) propylene glycol, USP and 20% (v/v) dehydrated alcohol, USP.
Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range. The mechanism of the antineoplastic effect of romidepsin observed in nonclinical and clinical studies has not been fully characterized.
Cardiac Electrophysiology
The effect of romidepsin on the heart-rate corrected QTc/QTcF was evaluated in 26 subjects with advanced malignancies given romidepsin at doses of 14 mg/m2 as a 4-hour intravenous infusion, and at doses of 8, 10 or 12 mg/m2 as a 1–hour infusion. Patients received premedications with antiemetics. No large changes in the mean QTc interval (> 20 milliseconds) from baseline based on Fridericia correction method were detected in the trial. Small increase in mean QT interval (< 10 milliseconds) and mean QT interval increase between 10 to 20 milliseconds cannot be excluded because of the limitations in the trial design.
Romidepsin was associated with a delayed concentration-dependent increase in heart rate in patients with advanced cancer with a maximum mean increase in heart rate of 20 beats per minute occurring at the 6 hour time point after start of romidepsin infusion for patients receiving 14 mg/m2 as a 4-hour infusion.
Absorption
Romidepsin exhibited linear pharmacokinetics across doses ranging from 1.0 to 24.9 mg/m2 when administered intravenously over 4 hours in patients with advanced cancers.
In patients with T-cell lymphomas who received 14 mg/m2 of romidepsin intravenously over a 4-hour period on days 1, 8, and 15 of a 28-day cycle, geometric mean values of the maximum plasma concentration (Cmax) and the area under the plasma concentration versus time curve (AUC0-inf) were 377 ng/mL and 1549 ng*hr/mL, respectively.
Distribution
Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL with α1-acid-glycoprotein (AAG) being the principal binding protein.
Metabolism
Romidepsin undergoes extensive metabolism in vitro primarily by CYP3A4 with minor contribution from CYP3A5, CYP1A1, CYP2B6, and CYP2C19. At therapeutic concentrations, romidepsin did not competitively inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 in vitro.
At therapeutic concentrations, romidepsin did not cause notable induction of CYP1A2, CYP2B6 and CYP3A4 in vitro. Therefore, pharmacokinetic drug-drug interactions are unlikely to occur due to CYP450 induction or inhibition by romidepsin when co-administered with CYP450 substrates.
Excretion
Following 4-hour intravenous administration of romidepsin at 14 mg/m2 on days 1, 8, and 15 of a 28-day cycle in patients with T-cell lymphomas, the terminal half-life (t1/2) was approximately 3 hours. No accumulation of plasma concentration of romidepsin was observed after repeated dosing.
Effect of Age, Gender or Race
The population pharmacokinetic analysis of romidepsin showed that age, gender, or race (white vs. black) did not appear to influence the pharmacokinetics of romidepsin.
Effect of Hepatic Impairment
No dedicated hepatic impairment study has been conducted for ISTODAX. The population pharmacokinetic analysis indicates that mild hepatic impairment [total bilirubin (TB) ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN; or TB > 1.0x - 1.5x ULN and any AST] had no significant influence on romidepsin pharmacokinetics. As the effect of moderate (TB > 1.5x - 3x ULN and any AST) and severe (TB > 3x ULN and any AST) hepatic impairment on the pharmacokinetics of romidepsin is unknown, patients with moderate and severe hepatic impairment should be treated with caution [See Use in Specific Populations (8.6)].
Effect of Renal Impairment
No dedicated renal impairment study has been conducted for ISTODAX. The population pharmacokinetic analysis showed that romidepsin pharmacokinetics were not affected by mild (estimated creatinine clearance 50 - 80 mL/min), moderate (estimated creatinine clearance 30 - 50 mL/min), or severe (estimated creatinine clearance < 30 mL/min) renal impairment. Nonetheless, the effect of end-stage renal disease on romidepsin pharmacokinetics has not been studied. Thus, patients with end-stage renal disease should be treated with caution [See Use in Specific Populations (8.7)].
Carcinogenicity studies have not been performed with romidepsin. Romidepsin was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or the mouse lymphoma assay. Romidepsin was not clastogenic in an in vivo rat bone marrow micronucleus assay when tested to the maximum tolerated dose (MTD) of 1 mg/kg in males and 3 mg/kg in females (6 and 18 mg/m2 in males and females, respectively). These doses were up to 1.3-fold the recommended human dose, based on body surface area.
Based on non-clinical findings, male and female fertility may be compromised by treatment with ISTODAX. In a 26-week toxicology study, romidepsin administration resulted in testicular degeneration in rats at 0.33 mg/kg/dose (2 mg/m2/dose) following the clinical dosing schedule. This dose resulted in AUC0-inf. values that were approximately 2% the exposure level in patients receiving the recommended dose of 14 mg/m2/dose. A similar effect was seen in mice after 4 weeks of drug administration at higher doses. Seminal vesicle and prostate organ weights were decreased in a separate study in rats after 4 weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m2/day), approximately 30% the estimated human daily dose based on body surface area. Romidepsin showed high affinity for binding to estrogen receptors in pharmacology studies. In a 26-week toxicology study in rats, atrophy was seen in the ovary, uterus, vagina and mammary gland of females administered doses as low as 0.1 mg/kg/dose (0.6 mg/m2/dose) following the clinical dosing schedule. This dose resulted in AUC0-inf. values that were 0.3% of those in patients receiving the recommended dose of 14 mg/m2/dose. Maturation arrest of ovarian follicles and decreased weight of ovaries were observed in a separate study in rats after four weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m2/day). This dose is approximately 30% the estimated human daily dose based on body surface area.
ISTODAX was evaluated in 2 multicenter, single-arm clinical studies in patients with CTCL. Overall, 167 patients with CTCL were treated in the US, Europe, and Australia. Study 1 included 96 patients with confirmed CTCL after failure of at least 1 prior systemic therapy. Study 2 included 71 patients with a primary diagnosis of CTCL who received at least 2 prior skin directed therapies or one or more systemic therapies. Patients were treated with ISTODAX at a starting dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days.
In both studies, patients could be treated until disease progression at the discretion of the investigator and local regulators. Objective disease response was evaluated according to a composite endpoint that included assessments of skin involvement, lymph node and visceral involvement, and abnormal circulating T-cells ("Sézary cells").
The primary efficacy endpoint for both studies was overall objective disease response rate (ORR) based on the investigator assessments, and defined as the proportion of patients with confirmed complete response (CR) or partial response (PR). CR was defined as no evidence of disease and PR as ≥50% improvement in disease. Secondary endpoints in both studies included duration of response and time to response.
Baseline Patient Characteristics
Demographic and disease characteristics of the patients in Study 1 and Study 2 are provided in Table 3.
Characteristic | Study 1 (N=96) | Study 2 (N=71) |
---|---|---|
Age | ||
N | 96 | 71 |
Mean (SD) | 57 (12) | 56 (13) |
Median (Range) | 57 (21, 89) | 57 (28, 84) |
Sex, n (%) | ||
Men | 59 (61) | 48 (68) |
Women | 37 (39) | 23 (32) |
Race, n (%) | ||
White | 90 (94) | 55 (77) |
Black | 5 ( 5) | 15 (21) |
Other/Not Reported | 1 ( 1) | 1 ( 1) |
Stage of Disease at Study Entry, n (%) | ||
IA | 0 ( 0) | 1 ( 1) |
IB | 15 (16) | 6 ( 9) |
IIA | 13 (14) | 2 ( 3) |
IIB | 21 (22) | 14 (20) |
III | 23 (24) | 9 (13) |
IVA | 24 (25) | 27 (38) |
IVB | 0 ( 0) | 12 (17) |
Number of Prior Skin-Directed Therapies | ||
Median (Range) | 2 (0,6) | 1 (0,3) |
Number of Prior Systemic Therapies | ||
Median (Range) | 2 (1, 8) | 2 (0, 7) |
Clinical Results
Efficacy outcomes for CTCL patients are provided in Table 4. Median time to first response was 2 months (range 1 to 6) in both studies. Median time to CR was 4 months in Study 1 and 6 months in Study 2 (range 2 to 9).
Response Rate | Study 1 (N=96) | Study 2 (N=71) |
---|---|---|
ORR (CR + PR), n (%) [95% Confidence Interval] | 33 (34) [25, 45] | 25 (35) [25, 49] |
CR, n (%) [95% Confidence Interval] | 6 (6) [2, 13] | 4 (6) [2, 14] |
PR, n (%) [95% Confidence Interval] | 27 (28) [19, 38] | 21 (30) [20, 43] |
Duration of Response (months) | ||
N | 33 | 25 |
Median (range) | 15 (1, 20*) | 11 (1, 66*) |
*denotes censored value |
ISTODAX was evaluated in a multicenter, single-arm, international clinical study in patients with PTCL who had failed at least 1 prior systemic therapy (Study 3). Patients in US, Europe and Australia were treated with ISTODAX at a dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days. Of the 131 patients treated, 130 patients had histological confirmation by independent central review and were evaluable for efficacy (HC Population). Six cycles of treatment were planned; patients who developed progressive disease (PD), significant toxicity, or who met another criterion for study termination were to discontinue treatment. Responding patients had the option of continuing treatment beyond 6 cycles at the discretion of the patient and Investigator until study withdrawal criteria were met.
Primary assessment of efficacy was based on rate of complete response (CR + CRu) as determined by an Independent Review Committee (IRC) using the International Workshop Response Criteria (IWC). Secondary measures of efficacy included IRC assessment of duration of response and objective disease response (ORR, CR + CRu + PR).
Baseline Patient Characteristics
Demographic and disease characteristics of the PTCL patients are provided in Table 5.
Characteristic | Study 3 (N=130) | Study 4 (N=47) |
---|---|---|
*Stage of disease was reported at time of diagnosis for Study 3 and at time of study entry for Study 4. | ||
Age (years), n | 130 | 47 |
Mean (SD) | 59 (13) | 59 (13) |
Median | 61 | 59 |
Sex, n (%) | ||
Male | 88 (68) | 25 (53) |
Female | 42 (32) | 22 (47) |
Race, n (%) | ||
White | 116 (89) | 40 (85) |
Black | 7 (5) | 4 (9) |
Asian | 3 (2) | 3 (6) |
Other | 4 (3) | 0 |
PTCL Subtype Based on Central Diagnosis, n (%) | ||
PTCL Unspecified (NOS) | 69 (53) | 28 (60) |
Angioimmunoblastic T-cell lymphoma (AITL) | 27 (21) | 7 (15) |
ALK-1 negative anaplastic large cell lymphoma (ALCL) | 21 (16) | 5 (11) |
Other | 13 (10) | 7 (16) |
Stage of Disease, n (%)* | ||
I/II | 39 (30) | 2 (4) |
III/IV | 91 (70) | 45 (96) |
ECOG Performance Status, n (%) | ||
0 | 46 (35) | 20 (43) |
1 | 67 (51) | 22 (47) |
2 | 17 (13) | 4 (9) |
Number of Prior Systemic Therapies | ||
Median (Range) | 2 (1, 8) | 3 (1, 6) |
All patients in both studies had received prior systemic therapy for PTCL. In Study 4, a greater percentage of patients had extensive prior radiation and chemotherapy. Twenty-one patients (16%) in Study 3 and 18 patients (38%) in Study 4 had received prior autologous stem cell transplant and 31 (24%) and 19 (40%) patients, respectively, had received prior radiation therapy.
Clinical Results
Efficacy outcomes for PTCL patients as determined by the IRC are provided in Table 6 for Study 3. The complete response rate was 15% and overall response rate was 25%. Similar complete response rates were observed by the IRC across the 3 major PTCL subtypes (NOS, AITL, and ALK-1 negative ALCL). Median time to objective response was 1.8 months (~2 cycles) for the 33 patients who achieved CR, CRu or PR and was 3.7 months (~4 cycles) for the 19 patients with complete response. The responses in 11 of the 19 patients achieving CR and CRu were known to exceed 9.2 months; the follow-up on the remaining 8 patients was discontinued prior to 9.2 months.
Response Rate | Study 3 (N=130) |
---|---|
1 Primary Endpoint | |
2 Secondary Endpoint | |
3 95% Confidence Interval | |
CR+CRu, n (%)1 | 19 (14.6) [9.0, 21.9]3 |
PR, n (%)2 | 14 (10.8) [6.0, 17.4]3 |
ORR (CR+CRu+PR), n (%)2 | 33 (25.4) [18.2, 33.8]3 |
In a second single-arm clinical study in patients with PTCL who had failed prior therapy (Study 4), patients were treated with ISTODAX at a starting dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days. Patients could be treated until disease progression at the discretion of the patient and the Investigator. The percentage of patients achieving CR + CRu in Study 4 was similar to that in Study 3.
ISTODAX is supplied as a kit including a sterile, lyophilized powder in a single-use vial containing 10 mg of romidepsin and 20 mg of the bulking agent, povidone, USP. In addition, each kit includes one sterile Diluent vial containing 2 mL (deliverable volume) of 80% propylene glycol, USP, and 20% dehydrated alcohol, USP.
NDC 59572-983-01: ISTODAX® KIT containing 1 vial of romidepsin, 10 mg and 1 vial of diluent for romidepsin, 2 mL per carton
ISTODAX (romidepsin) for injection is supplied as a kit containing two vials in a single carton. The carton must be stored at 20° to 25°C, excursions permitted between 15° to 30°C. (See USP Controlled Room Temperature.)
Keep out of reach of children.
Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published1-4[See References (15)].
See FDA-approved patient labeling.
Manufactured for:
Celgene Corporation
Summit, NJ 07901
Manufactured by:
Ben Venue Laboratories, Inc.
Bedford, OH 44146
or
© 2010-2012 Celgene Corporation. All Rights Reserved.
U.S. Patents: 4,977,138; 7,608,280; 7,611,724
ISTBAXPI.004/PPI.004 03/12
Patient Medication Information
ISTODAX (ISS toe dax) (romidepsin) for injection
Read the patient information that comes with ISTODAX before you receive your first treatment and each time before you are treated. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.
What is ISTODAX?
ISTODAX is a prescription medicine used to treat people with a type of cancer called cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) after at least one other type of medicine by mouth or injection has been tried.
It is not known if ISTODAX is safe and effective in children under 18 years of age.
What should I tell my doctor before I receive ISTODAX?
Before receiving ISTODAX, tell your doctor if you:
Tell your doctor about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements and any recent changes in medications.
Some medicines may affect how ISTODAX works, or ISTODAX may affect how your other medicines work. Especially tell your doctor if you take or use:
Ask your doctor if you are not sure if your medicine is one that is listed above. Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.
How should I take ISTODAX?
What are the possible side effects of ISTODAX?
ISTODAX may cause serious side effects, including:
|
|
Common side effects of ISTODAX include:
Tell your doctor if you have any side effect that bothers you or does not go away.
These are not all the possible side effects of ISTODAX. For more information, ask your doctor or pharmacist.
Ask your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about ISTODAX
Medicines are sometimes prescribed for purposes other than those listed in patient information leaflets.
This patient information leaflet summarizes the most important information about ISTODAX. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ISTODAX that is written for health professionals. For more information, go to www.ISTODAX.com or call 1-888-423-5436.
What are the ingredients in ISTODAX?
Active ingredient: romidepsin
Inactive ingredients: povidone. The diluent contains 80% propylene glycol and 20% dehydrated alcohol.
This Patient Information has been approved by the U.S. Food and Drug Administration.
Manufactured for:
Celgene Corporation
Summit, NJ 07901
ISTODAX® is a registered trademark of Celgene Corporation
©2010-2012 Celgene Corporation. All Rights Reserved.
U.S. Patents: 4,977,138; 7,608,280; 7,611,724
ISTBAXPPI.004 03/12
Approved March/2012
ISTODAX
romidepsin kit |
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
Labeler - Celgene Corporation (174201137) |
Registrant - Celgene Corporation (174201137) |